These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 25027075)

  • 1. Progeria: a rare genetic premature ageing disorder.
    Sinha JK; Ghosh S; Raghunath M
    Indian J Med Res; 2014 May; 139(5):667-74. PubMed ID: 25027075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-Molecule Therapeutic Perspectives for the Treatment of Progeria.
    Macicior J; Marcos-Ramiro B; Ortega-Gutiérrez S
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progeria syndromes and ageing: what is the connection?
    Burtner CR; Kennedy BK
    Nat Rev Mol Cell Biol; 2010 Aug; 11(8):567-78. PubMed ID: 20651707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA approval summary for lonafarnib (Zokinvy) for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies.
    Suzuki M; Jeng LJB; Chefo S; Wang Y; Price D; Li X; Wang J; Li RJ; Ma L; Yang Y; Zhang X; Zheng N; Zhang K; Joseph DB; Shroff H; Doan J; Pacanowski M; Smpokou P; Donohue K; Joffe HV
    Genet Med; 2023 Feb; 25(2):100335. PubMed ID: 36507973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progeria of stem cells: stem cell exhaustion in Hutchinson-Gilford progeria syndrome.
    Halaschek-Wiener J; Brooks-Wilson A
    J Gerontol A Biol Sci Med Sci; 2007 Jan; 62(1):3-8. PubMed ID: 17301031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progeria-a Rare Genetic Condition with Accelerated Ageing Process.
    Talukder P; Saha A; Roy S; Ghosh G; Dutta Roy D; Barua S
    Appl Biochem Biotechnol; 2023 Apr; 195(4):2587-2596. PubMed ID: 35445924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of musculoskeletal phenotype of the G608G progeria mouse model with lonafarnib, pravastatin, and zoledronic acid as treatment groups.
    Cubria MB; Suarez S; Masoudi A; Oftadeh R; Kamalapathy P; DuBose A; Erdos MR; Cabral WA; Karim L; Collins FS; Snyder BD; Nazarian A
    Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12029-12040. PubMed ID: 32404427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A progeroid syndrome in mice is caused by defects in A-type lamins.
    Mounkes LC; Kozlov S; Hernandez L; Sullivan T; Stewart CL
    Nature; 2003 May; 423(6937):298-301. PubMed ID: 12748643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extraskeletal Calcifications in Hutchinson-Gilford Progeria Syndrome.
    Gordon CM; Cleveland RH; Baltrusaitis K; Massaro J; D'Agostino RB; Liang MG; Snyder B; Walters M; Li X; Braddock DT; Kleinman ME; Kieran MW; Gordon LB
    Bone; 2019 Aug; 125():103-111. PubMed ID: 31077852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progeria and the early aging in children: a case report.
    Carvalho VO; Celli A; Bancke Laverde BL; Cunico C; Santos Piedade G; Lucas de Mello M; Beirao Junior PS
    Dermatol Online J; 2016 Feb; 22(2):. PubMed ID: 27267192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome.
    Gordon LB; Kleinman ME; Massaro J; D'Agostino RB; Shappell H; Gerhard-Herman M; Smoot LB; Gordon CM; Cleveland RH; Nazarian A; Snyder BD; Ullrich NJ; Silvera VM; Liang MG; Quinn N; Miller DT; Huh SY; Dowton AA; Littlefield K; Greer MM; Kieran MW
    Circulation; 2016 Jul; 134(2):114-25. PubMed ID: 27400896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mini-Review: molecular elucidations of hutchinson-gilford progeria syndrome: A hope for managing horrors of premature aging in children.
    Ahmed B; Basheer R; Irfan M; Hamid Akash MS; Muhammad SA; Qadir MI
    Pak J Pharm Sci; 2020 May; 33(3):1179-1182. PubMed ID: 33191246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hutchinson-Gilford Progeria Syndrome: Cardiovascular Pathologies and Potential Therapies.
    Xu S; Jin ZG
    Trends Biochem Sci; 2019 Jul; 44(7):561-564. PubMed ID: 31036409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hutchinson-Gilford progeria syndrome: clinical and molecular analysis in an African patient].
    Mutesa L; Pierquin G; Cwiny-Ay N; Buzizi P; Bours V
    Rev Med Liege; 2007 Mar; 62(3):155-8. PubMed ID: 17511383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prematurely aged children: molecular alterations leading to Hutchinson-Gilford progeria and Werner syndromes.
    Domínguez-Gerpe L; Araújo-Vilar D
    Curr Aging Sci; 2008 Dec; 1(3):202-12. PubMed ID: 20021393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic involvement in Hutchinson-Gilford progeria syndrome: a mini-review.
    Arancio W; Pizzolanti G; Genovese SI; Pitrone M; Giordano C
    Gerontology; 2014; 60(3):197-203. PubMed ID: 24603298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hutchinson-Gilford progeria syndrome: report of 2 cases and a novel LMNA mutation of HGPS in China.
    Zhang H; Chen X; Guo Y; Liang J; Tang L; Yu H; Yao Z
    J Am Acad Dermatol; 2013 Oct; 69(4):e175-6. PubMed ID: 24034385
    [No Abstract]   [Full Text] [Related]  

  • 18. Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome.
    Gordon LB; Shappell H; Massaro J; D'Agostino RB; Brazier J; Campbell SE; Kleinman ME; Kieran MW
    JAMA; 2018 Apr; 319(16):1687-1695. PubMed ID: 29710166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are there Different Kinds of Aging?
    Diaconeasa AG; Rachita M
    Curr Aging Sci; 2018; 11(1):55-62. PubMed ID: 29149836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lamin A-linked progerias: is farnesylation the be all and end all?
    Smallwood DT; Shackleton S
    Biochem Soc Trans; 2010 Feb; 38(Pt 1):281-6. PubMed ID: 20074075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.